Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
Conditions: Non Small Cell Lung Cancer; EGFR Gene Mutation Interventions: Drug: almonertinib; Drug: Carboplatin; Drug: Nab paclitaxel Sponsors: Guangdong Provincial People ' s Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Genetics | Hospitals | Immunotherapy | Lung Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Research